24.48
-1.02(-4.00%)
Currency In USD
| Previous Close | 25.5 |
| Open | 25.36 |
| Day High | 25.54 |
| Day Low | 24.22 |
| 52-Week High | 47 |
| 52-Week Low | 14.4 |
| Volume | 1.61M |
| Average Volume | 1.1M |
| Market Cap | 1.63B |
| PE | -8.13 |
| EPS | -3.01 |
| Moving Average 50 Days | 21.88 |
| Moving Average 200 Days | 22.33 |
| Change | -1.02 |
If you invested $1000 in Celldex Therapeutics, Inc. (CLDX) 10 years ago, it would be worth $103.88 as of August 18, 2025 at a share price of $24.48. Whereas If you bought $1000 worth of Celldex Therapeutics, Inc. (CLDX) shares 5 years ago, it would be worth $2,130.55 as of August 18, 2025 at a share price of $24.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
GlobeNewswire Inc.
Jun 14, 2025 2:48 PM GMT
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
GlobeNewswire Inc.
Jun 12, 2025 10:01 PM GMT
Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0)48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1)KIT related tolerability events
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
GlobeNewswire Inc.
Jun 10, 2025 8:01 PM GMT
Company to host webcast on Thursday, June 12 at 6:00 pm ETHAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company’s Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be pr